Monoclonal antibodies targeting IL-33, such as tozorakimab and itepekimab, are currently in clinical trials for chronic obstructive pulmonary disease (NCT05166889 and NCT05158387), asthma (NCT04570657), and acute respiratory failure (NCT05624450) and might be repurposed for PAH. The gene discussed is IL33; the disease is asthma.